ABCC8 and neonatal diabetes mellitus: All the permanent NDM patients with KCNJ11 and ABCC8 mutations were successfully transferred to SU treatment, resulting in a significant increase in C-peptide level after three months, better glycemic regulation, and discontinuation of insulin (Table 2). SU was started at a dose of 0.2 mg/kg/day, twice a day.